For pricing in CAD please contact us.

DLAC Reagent - 250mg

DLAC Reagent - 250mg

Regular price
$220.69 USD
Regular price
Sale price
$220.69 USD
Unit price
Sold out

CALIXAR’s DLAC reagent is a non-ionic detergent/surfactant with a lactobionamide head group and a decyl chain.
Compound name: N-decylamine lactobionamide (DLAC)

Catalogue number: DLAC _250MG 

Molec. Formula: C22H43NO11

CAS: nd

MW: 497.6 g/mol

pKa: na​

Percent Composition: C, 53.1; H, 8.71; N, 2.81; O, 35.37


Physical state: White powder

Purity (HPLC, 214nm): 97%

Retention time (RP18 HPLC)b: R = 10.6 min

CMC: 1.3 mM

Exact mass​: 497.2836

Stability: Store in <-20°C freezer for up to one year

Solubility Structure: Soluble in water (65mM), methanol and DMSO


CALIXAR uses a unique & custom-established procedure 

CALIXAR’s DLAC is provided to clients in a powder form and is used in aqueous solutions or buffers. DLAC can be processed with biological materials (biological membranes).

Clients are able to use DLAC to better produce lipid detergents, mixed micelles, and protein detergent micelles. DLAC provides our clients with a way to extract, to solubilize and to stabilize native and functional membrane proteins.

DLAC is a quite mild detergent to extract, to solubilize and to stabilize native membrane proteins. As DDLAC is non-ionic. Therefore, it is not sensitive to ionic strength or pH variations which is ideal to extract, to solubilize and to stabilize specific membrane proteins of high medical relevance.


CALIXAR’s DLAC is non-ionic and therefore not susceptible to ionic strength or pH variations. It is specifically built to extract, solubilize and stabilize precise membrane proteins.


CALIXAR’s DLAC (N-decylamine lactobionamide) extracts high-quality membrane proteins utilized for research, drug discovery projects and structural studies. They are used by pharmaceutical firms, biotechnology companies, and academic teams (biochemists, structural biologists, pharmacologists, virologists) that are committed to the life science disciplines.


  • Antibodies (including nanobodies, scaffold proteins, aptamers)
  • Small molecules
  • 3D Structures (cryoEM, XRay crystallography, NMR, SANS, SAXS)
  • Drug discovery (Screening: HTS, FBDD, SBDD; Hit and lead validation)
  • Antibody discovery (Immunization and display technologies)
  • Clinical stage



Lactobionamide Surfactants with Hydrogenated, Perfluorinated or Hemifluorinated Tails

Lebaupain F. et al. 2006